Navigation Links
Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
Date:2/6/2008

opharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's clinical development plans and the potential for vicriviroc. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details of these and other risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A, "Risk Factors" in the company's third quarter 2007 10-Q.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
2. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
3. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
4. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
5. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
6. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
7. New Study Data Published in British Journal of Urology Demonstrates Cryoablation Effective for Kidney Cancer
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
9. First in the World Live Case Using New Technology Demonstrates Shorter Procedure Time
10. Study Shows Organons Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
11. US Preventive Medicine(R) Says Study on Heart Disease-related Deaths Demonstrates Need for Preventive Medical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... program could help doctors predict which patients might suffer ... , The program, which assesses brain scans using pattern ... and passport control, has been developed by researchers at ... by the Wellcome Trust, which used the software are ... , Stroke affects over 15 million people each year ...
(Date:4/23/2014)... showing the potential health benefits of probiotics, antioxidants and ... supplements. And the chemical industry is getting in on ... could deter growth, so the industry is responding with ... the cover story in Chemical & Engineering News ... Chemical Society. , Melody M. Bomgardner, a senior editor ...
(Date:4/23/2014)... Five for-profit and non-profit organizations in Washington will ... of Concept grants to accelerate maturation of promising ... Life Sciences Discovery Fund (LSDF) announced today. Also ... to the Washington Biotechnology & Biomedical Association (WBBA) ... the next generation of entrepreneurs and help early-stage ...
(Date:4/23/2014)... Midlife Occupational and Leisure Time Physical Activity on Mobility ... in midlife increases the risk of mobility limitation in ... This is found in a study which followed up ... was conducted at the Gerontology Research Center in Finland ... physical labor is often repetitive, wears the body and ...
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
Breaking Medicine News(10 mins):Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... , WASHINGTON, Sept. 18 In the ... is considered a "pre-existing condition" by many health insurers, today ... police officers, war correspondents, expectant fathers, pregnant women and patients ... denied health insurance policies. , , The ...
... various routes , FRIDAY, Sept. 18 (HealthDay News) -- ... the U.S. Food and Drug Administration can be safely ... new recommendations from the American Academy of Allergy, Asthma ... responses are weakened by medical treatments (such as for ...
... , SAN FRANCISCO, Sept. 18 Quantros(TM), ... healthcare industry, today announced a partnership with HealthWatch, Inc. - a ... Care, a national, not for profit quality improvement organization - to ... , , Quantros Patient Safety Center (QPSC(TM)), the ...
... Sept. 18 happier.com is a ... designed to help people not just be happier but "do happier. ... for users to make an immediate positive impact on ... by taking 4 validated tests with instant feedback on ...
... , Active sculptor and wood carver makes quick return ... six years of dialysis finally began to take a heavy toll on 84-year-old ... his art, and he was unable to travel, which is a major source ... patriarch to an expansive family. He,s the father of four, grandfather of five ...
... SHANGHAI, Sept. 18 /PRNewswire-Asia/ -- Avery Dennison Specialty Tape,Division, ... sector,introduced two new ultra-thin adhesives and a hydrocolloid and ... (Photo: http://www.prnasia.com/sa/2009/09/18/20090918839634.html ) , ... entire spectrum of wound care and for the most,demanding ...
Cached Medicine News:Health News:Pre-Existing Health 'Conditions' - Cops, Firefighters, Expectant Dads, and Those Suffering From Allergies, Acne and Toenail Fungus Are Uninsurable According to Internal Documents 2Health News:Swine Flu Shots Safe for People With Weak Immune Systems: Experts 2Health News:Swine Flu Shots Safe for People With Weak Immune Systems: Experts 3Health News:Quantros and HealthWatch Announce PSO Partnership 2Health News:Quantros and HealthWatch Announce PSO Partnership 3Health News:https://happier.com/form.htmhappier.com Launches a Personal Trainer for Your Happiness 2Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 2Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 3Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 4Health News:Avery Dennison Introduces Advanced New Medical Dressing Technology at MEDTEC China 2009 2Health News:Avery Dennison Introduces Advanced New Medical Dressing Technology at MEDTEC China 2009 3
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... 15, 2011 Amgen (NASDAQ: AMGN ... District Court in Pennsylvania has entered final judgment ... Ltd. and Teva Pharmaceuticals USA prohibiting them from ... colony-stimulating factor) and methods for its use. Today,s ...
... key component of health care reform involves the improvement ... particularly for patients admitted to a hospital. To help ... Center for Health Quality and Innovation, which provides financial ... system. The center has now awarded nine ...
Cached Medicine Technology:Amgen Resolves G-CSF Patent Litigation With Teva 2UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 2UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 3UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 4UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 5
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
... The Aquarius 384 is a ... Aquarius 384-well head is a unique ... washing using the included wash system. ... 250 microplate stacker system. Will ...
... new Nanopipetting System Genesis NPS based on ... allows you to miniaturize your assays for ... picking and direct dilutions., Furthermore it ... applications including gene expression analysis, gene mapping, ...
Medicine Products: